We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

222 hedge funds and large institutions have $3.2B invested in Amicus Therapeutics in 2022 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 75 increasing their positions, 71 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more call options, than puts

Call options by funds: $8.09M | Put options by funds: $5.04M

59% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 22

5% more funds holding

Funds holding: 212222 (+10)

6% more repeat investments, than reductions

Existing positions increased: 75 | Existing positions reduced: 71

0.61% more ownership

Funds ownership: 108.94%109.55% (+0.61%)

2% less capital invested

Capital invested by funds: $3.27B → $3.2B (-$68.2M)

14% less funds holding in top 10

Funds holding in top 10: 76 (-1)

Holders
222
Holders Change
+10
Holders Change %
+4.72%
% of All Funds
3.82%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.1%
New
35
Increased
75
Reduced
71
Closed
22
Calls
$8.09M
Puts
$5.04M
Net Calls
+$3.06M
Net Calls Change
-$5.41M
Name Holding Trade Value Shares
Change
Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$309M +$142M +12,772,089 +76%
PA
2
Perceptive Advisors
New York
$286M +$5.32M +477,385 +2%
ACA
3
Avoro Capital Advisors
New York
$280M
Vanguard Group
4
Vanguard Group
Pennsylvania
$270M +$1.55M +138,973 +0.5%
RG
5
Redmile Group
California
$227M -$4.9M -439,700 -2%
BlackRock
6
BlackRock
New York
$208M -$3.91M -351,306 -2%
Morgan Stanley
7
Morgan Stanley
New York
$179M -$12.6M -1,130,067 -6%
JP Morgan Chase
8
JP Morgan Chase
New York
$150M -$17M -1,526,402 -10%
State Street
9
State Street
Massachusetts
$126M -$21.1M -1,896,103 -14%
PAI
10
Palo Alto Investors
California
$103M
Wellington Management Group
11
Wellington Management Group
Massachusetts
$84.1M -$33.1M -2,968,369 -27%
Macquarie Group
12
Macquarie Group
Australia
$71.8M +$1.23M +110,515 +2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$49.3M +$709K +63,632 +1%
Norges Bank
14
Norges Bank
Norway
$45.5M +$16.8M +1,511,838 +53%
AG
15
Artal Group
Luxembourg
$41.8M
Fiera Capital (Canada)
16
Fiera Capital (Canada)
Quebec, Canada
$38.1M -$739K -66,317 -2%
PAMS
17
Pictet Asset Management (Switzerland)
Switzerland
$36.4M +$31.7M +2,842,220 +442%
D.E. Shaw & Co
18
D.E. Shaw & Co
New York
$30.3M -$727K -65,240 -2%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$29.2M +$8.29M +744,451 +36%
Northern Trust
20
Northern Trust
Illinois
$27.8M -$339K -30,413 -1%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
21
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$27.4M +$9.85M +884,400 +51%
BC
22
Boxer Capital
California
$24.3M
NHAS
23
Novo Holdings A/S
Denmark
$21.9M -$5.96M -535,000 -20%
William Blair Investment Management
24
William Blair Investment Management
Illinois
$21.8M -$5.15M -462,242 -18%
Bank of America
25
Bank of America
North Carolina
$21.6M +$1.2M +107,592 +5%

FOLD Hedge Fund Activity: Q3 2022 in Review

222 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2022, worth a combined $3.2B — down 2.1% from $3.27B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new FOLD positions and 22 closed out — a net gain of 13 holders — while 75 added to existing stakes and 71 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $142M. The largest seller was Deutsche Bank, cutting an estimated $52.7M.

  • 222 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2022, up from 212 in Q2 2022.
  • Funds reported $3.2B of Amicus Therapeutics stock for Q3 2022, down 2.1% quarter-over-quarter.
  • 35 funds opened new Amicus Therapeutics positions in Q3 2022 and 22 closed out, a net change of +13 holders.
  • The largest Amicus Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $142M added.
  • The largest Amicus Therapeutics seller in Q3 2022 was Deutsche Bank, an estimated $52.7M sold.

Based on aggregated 13F filings for Q3 2022.